Paroxysmal Nocturnal Hemoglobinuria: What to Do When Eculizumab, Ravulizumab, or Crovalimab Fails to Achieve Complete Hematologic Response
In symptomatic hemolytic PNH, first-line terminal C5 inhibitor therapy is the established starting point. When that treatment does not achieve a complete hematologic response — or when extravascular hemolysis becomes clinically relevant — a defined next-line protocol applies.
Previous Treatment & Reason for Escalation
Prior therapy: First-line terminal C5 inhibitor — eculizumab, ravulizumab, or crovalimab — for symptomatic hemolytic PNH.
Escalation trigger: Failure to reach complete hematologic response, assessed as the median over 6 months: transfusion still required, hemoglobin below 12 g/dl, LDH exceeding 1.5× the upper limit of normal, or reticulocytes above 150/nl.
Next-Line Approach — Partial Overview
When extravascular hemolysis becomes clinically relevant on terminal C5 inhibitor therapy, the protocol calls for escalating to proximal complement inhibition — either as a switch or as an add-on to ongoing treatment. Several agents within this class are covered, with distinct administration routes and sequences addressed in the full protocol.
Complete selection criteria, agent options, and the full regimen are available in the structured protocol below.
Target: ↑ Hemoglobin & reticulocytes → normal range
References
- This extravascular hemolysis (EVH) can become clinically relevant in some patients and might necessitate a switch to (or addition of) a proximal complement inhibitor.
- In this study too, there was a significant improvement in hemoglobin levels and a drop in reticulocytes to the normal range on average.
View source ↗